Article information
Resumen
Citomegalovirus (CMV) es el patógeno oportunista más importante en el paciente sometido a un trasplante de órgano, incrementando la mortalidad del paciente debido a efectos directos e indirectos. El factor de riesgo más importante para el desarrollo de enfermedad por CMV es la discordancia serológica para CMV entre donante y receptor (donante positivo y receptor negativo), que supone un riesgo de más del 50% de desarrollo de enfermedad por CMV si no se administra profilaxis. El uso de fármacos antivirales muy potentes para la profilaxis de esta complicación en pacientes de alto riesgo ha modificado las características de la enfermedad por CMV en esta población. Otros factores de riesgo clásicos para el desarrollo de enfermedad por CMV incluyen el desarrollo de rechazo agudo del injerto, tipo de órgano trasplantado, coinfección con otros herpesvirus y el tipo de inmunosupresores empleado. Recientemente se han descrito nuevos factores de riesgo para el desarrollo de esta complicación que incluyen las variaciones de genotipo de CMV entre donante y receptor, y alteraciones genéticas de la inmunidad innata en el receptor. En esta revisión se abordan los factores de riesgo clásicos y los últimos hallazgos descritos para el desarrollo de enfermedad por CMV en el receptor de un trasplante de órgano.
Palabras clave:
Enfermedad por CMV
Factores de riesgo
Trasplante de órgano sólido
Discordancia serológica
Rechazo agudo del injerto
Inmunosupresión
Herpesvirus
Polimorfismos genéticos
Abstract
Cytomegalovirus (CMV) is the most important opportunistic pathogen in patients undergoing solid organ transplantation and increases mortality due to both direct and indirect effects. The most important risk factor for the development of CMV disease is discordant donor-recipient CMV serology (positive donor and negative recipient), which confers more than 50% risk of developing CMV disease if no prophylaxis is given. The use of highly potent antiviral agents for CMV prophylaxis in high-risk patients has changed the characteristics of CMV disease in this population. Other classical risk factors for CMV disease include acute graft rejection, the type of organ transplanted, coinfection with other herpesviruses and the type of immunosuppressive agents employed. New risk factors for this complication have recently been described, including variations in the CMV genotype between donor and recipient and genetic alterations in the recipient's innate immunity. The present review discusses classical risk factors and the latest findings reported on the development of CMV in organ transplant recipients.
Keywords:
CMV disease
Risk factors
Solid organ transplant
Serological discordance
Acute graft rejection
Immunosuppression
Herpesvirus
Genetic polymorphisms
Full text is only aviable in PDF
Bibliografía
[1.]
J. Sinclair, P. Sissons.
Latent and persistent infections of monocytes and macrophages.
Intervirology, 39 (1996), pp. 293-301
[2.]
R.H. Rubin.
Cytomegalovirus in solid organ transplantation.
Transpl Infect Dis, 3 (2001), pp. 1-5
[3.]
S. Sagedal, K.P. Nordal, A. Hartmann, M. Degre, E. Holter, A. Foss, et al.
A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients.
Transplantation, 70 (2000), pp. 1166-1174
[4.]
S.A. Staras, S.C. Dollard, K.W. Radford, W.D. Flanders, R.F. Pass, M.J. Cannon.
Seroprevalence of cytomegalovirus infection in the United States, 1988–1994.
Clin Infect Dis, 43 (2006), pp. 1143-1151
[5.]
F. De Ory, R. Ramírez, L. García Comas, P. León, M.J. Sagues, J.C. Sanz.
Is there a change in cytomegalovirus seroepidemiology in Spain?.
Eur J Epidemiol, 19 (2004), pp. 85-89
[6.]
V.R. Dharnidharka, L.Y. Agodoa, K.C. Abbott.
Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients--an analysis of USRDS data.
Am J Transplant, 7 (2007), pp. 653-661
[7.]
San Juan R, Aguado JM, Lumbreras C, Fortún J, Muñoz P, Gavaldá J, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis. 20081;47:875–82.
[8.]
C. Cervera, M. Pineda, L. Linares, M.A. Marcos, C. Esteva, A. Antón, et al.
Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Transplant Proc, 39 (2007), pp. 2228-2230
[9.]
D. Lowance, H.H. Neumayer, C.M. Legendre, J.P. Squifflet, J. Kovarik, P.J. Brennan, et al.
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
N Engl J Med, 340 (1999), pp. 1462-1470
[10.]
D.J. Winston, D.K. Imagawa, C.D. Holt, F. Kaldas, A. Shaked, R.W. Busuttil.
Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
Transplantation, 60 (1995), pp. 1357-1360
[11.]
S. Noble, D. Faulds.
Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Drugs, 56 (1998), pp. 115-146
[12.]
P. Seu, D.J. Winston, C.D. Holt, F. Kaldas, R.W. Busuttil.
Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMVseronegative liver transplant recipients with CMV-seropositive donors.
Transplantation, 64 (1997), pp. 1614-1617
[13.]
E. Gane, F. Saliba, G.J. Valdecasas, J. O’Grady, M.D. Pescovitz, S. Lyman, et al.
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liveR–transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
Lancet, 350 (1997), pp. 1729-1733
[14.]
M.D. Pescovitz, T.L. Pruett, T. Gonwa, B. Brook, R. McGory, K. Wicker, et al.
Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
Transplantation, 66 (1998), pp. 1104-1107
[15.]
A.P. Limaye, L. Corey, D.M. Koelle, C.L. Davis, M. Boeckh.
Emergence of gancicloviR–resistant cytomegalovirus disease among recipients of solid-organ transplants.
Lancet, 356 (2000), pp. 645-649
[16.]
M.D. Pescovitz, J. Rabkin, R.M. Merion, C.V. Paya, J. Pirsch, R.B. Freeman, et al.
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.
Antimicrob Agents Chemother, 44 (2000), pp. 2811-2815
[17.]
C. Paya, A. Humar, E. Domínguez, K. Washburn, E. Blumberg, B. Alexander, et al.
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Am J Transplant, 4 (2004), pp. 611-620
[18.]
A.P. Limaye, R. Bakthavatsalam, H.W. Kim, C.S. Kuhr, J.B. Halldorson, P.J. Healey, et al.
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.
Transplantation, 78 (2004), pp. 1390-1396
[19.]
S.K. Arthurs, A.J. Eid, R.A. Pedersen, W.K. Kremers, F.G. Cosio, R. Patel, et al.
Delayedonset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
Clin Infect Dis, 46 (2008), pp. 840-846
[20.]
N. Singh.
Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy.
Rev Med Virol, 16 (2006), pp. 281-287
[21.]
A. Humar, T. Mazzulli, G. Moussa, R.R. Razonable, C.V. Paya, M.D. Pescovitz, et al.
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R–transplant recipients.
Am J Transplant, 5 (2005), pp. 1065-1070
[22.]
O.J. Benmarzouk-Hidalgo, E. Cordero, A. Martín-Pena, E. García-Prado, M.A. Gentil, M.A. Gómez-Bravo, et al.
Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection.
Antivir Ther, 14 (2009), pp. 641-647
[23.]
O.J. Benmarzouk-Hidalgo, J.M. Cisneros, E. Cordero, A. Martín-Pena, B. Sánchez, C. Martín-Gandul, et al.
Therapeutic effect of the acquisition of cytomegalovirusspecific immune response during preemptive treatment.
Transplantation, 91 (2011), pp. 927-933
[24.]
N. Kunzle, C. Petignat, P. Francioli, G. Vogel, C. Seydoux, J.M. Corpataux, et al.
Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity.
Transpl Infect Dis, 2 (2000), pp. 118-126
[25.]
R. San Juan, M. Yebra, C. Lumbreras, F. López-Medrano, M. Lizasoain, J.C. Meneu, et al.
A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R–) solid organ transplant recipients.
Clin Transplant, 23 (2009), pp. 666-671
[26.]
F.L. Luan, L.J. Stuckey, J.M. Park, D. Kaul, D. Cibrik, A. Ojo.
Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.
J Am Soc Nephrol, 20 (2009), pp. 2449-2458
[27.]
A. Humar, A.P. Limaye, E.A. Blumberg, I.A. Hauser, F. Vincenti, A.G. Jardine, et al.
Extended valganciclovir prophylaxis in D+/R– kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
Transplantation, 90 (2010), pp. 1427-1431
[28.]
K. Ishibashi, T. Tokumoto, K. Tanabe, H. Shirakawa, K. Hashimoto, N. Kushida, et al.
Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes.
Clin Infect Dis, 45 (2007), pp. 60-67
[29.]
S.W. Chou, K.M. Dennison.
Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes.
J Infect Dis, 163 (1991), pp. 1229-1234
[30.]
O. Manuel, X.L. Pang, A. Humar, D. Kumar, K. Doucette, J.K. Preiksaitis.
An assessment of donor–to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.
J Infect Dis, 199 (2009), pp. 1621-1628
[31.]
O. Manuel, A. Asberg, X. Pang, H. Rollag, V.C. Emery, J.K. Preiksaitis, et al.
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solidorgan transplant recipients with cytomegalovirus disease.
Clin Infect Dis, 49 (2009), pp. 1160-1166
[32.]
A.D. Kirk.
Induction immunosuppression.
Transplantation, 82 (2006), pp. 593-602
[33.]
P. Martín-Dávila, M. Blanes, J. Fortun.
Immunosuppression and infection in transplant recipients.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 143-154
[34.]
A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group.
N Engl J Med, 313 (1985), pp. 337-342
[35.]
J.F. Whiting, S.J. Rossi, D.W. Hanto.
Infectious complications after OKT3 induction in liver transplantation.
Liver Transpl Surg, 3 (1997), pp. 563-570
[36.]
M.A. Hooks, C.A. Perlino, J.M. Henderson, W.J. Millikan Jr., M.H. Kutner.
Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation.
Ann Pharmacother, 26 (1992), pp. 617-620
[37.]
B. Charpentier, L. Rostaing, F. Berthoux, P. Lang, G. Civati, J.L. Touraine, et al.
A threearm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
Transplantation, 75 (2003), pp. 844-851
[38.]
A.C. Webster, E.G. Playford, G. Higgins, J.R. Chapman, J.C. Craig.
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.
Transplantation, 77 (2004), pp. 166-176
[39.]
D.C. Brennan, J.A. Daller, K.D. Lake, D. Cibrik, D. Del Castillo.
Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
N Engl J Med, 355 (2006), pp. 1967-1977
[40.]
M.J. Hanaway, E.S. Woodle, S. Mulgaonkar, V.R. Peddi, D.B. Kaufman, M.R. First, et al.
Alemtuzumab induction in renal transplantation.
N Engl J Med, 364 (2011), pp. 1909-1919
[41.]
A.Y. Peleg, S. Husain, E.J. Kwak, F.P. Silveira, M. Ndirangu, J. Tran, et al.
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
Clin Infect Dis, 44 (2007), pp. 204-212
[42.]
Y. Baez, F. Girón, A. Nino-Murcia, J. Rodríguez, S. Salcedo.
Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
Transplant Proc, 40 (2008), pp. 697-699
[43.]
S. Hadley, M.H. Samore, W.D. Lewis, R.L. Jenkins, A.W. Karchmer, S.M. Hammer.
Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.
Transplantation, 59 (1995), pp. 851-859
[44.]
J.M. Sarmiento, D.H. Dockrell, T.R. Schwab, S.R. Munn, C.V. Paya.
Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients.
Clin Transplant, 14 (2000), pp. 136-138
[45.]
M. Bernabeu-Wittel, M. Naranjo, J.M. Cisneros, E. Canas, M.A. Gentil, G. Algarra, et al.
Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 173-180
[46.]
M.A. Muñoz, A. Andrés, R. Gallego, E. Morales, J.M. Morales, J.M. Aguado, et al.
Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
Transplant Proc, 34 (2002), pp. 97
[47.]
M. Vigano, T. Dengler, M.F. Mattei, A. Poncelet, J. Vanhaecke, E. Vermes, et al.
Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
Transpl Infect Dis, 12 (2010), pp. 23-30
[48.]
Cervera C, Fernández-Ruiz M, Valledor A, Linares L, Antón A, Marcos MA, et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis. Apr 27.
[49.]
J.K. Kirklin, D.C. Naftel, T.B. Levine, R.C. Bourge, G.B. Pelletier, J. O’Donnell, et al.
Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group.
J Heart Lung Transplant, 13 (1994), pp. 394-404
[50.]
R. Manez, S. Kusne, M. Green, K. Abu-Elmagd, W. Irish, J. Reyes, et al.
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.
Transplantation, 59 (1995), pp. 1010-1014
[51.]
D.B. Kaufman, J.R. Leventhal, L.G. Gallon, M.A. Parker, A.J. Koffron, J.P. Fryer, et al.
Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
Transplantation, 72 (2001), pp. 1940-1945
[52.]
G. Guaraldi, S. Cocchi, M. Codeluppi, F. Di Benedetto, N. De Ruvo, M. Masetti, et al.
Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients.
Transplantation, 80 (2005), pp. 1742-1748
[53.]
C. Lumbreras, I. Fernández, J. Velosa, S. Munn, S. Sterioff, C.V. Paya.
Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome.
Clin Infect Dis, 20 (1995), pp. 514-520
[54.]
B.D. Alexander, V.F. Tapson.
Infectious complications of lung transplantation.
Transpl Infect Dis, 3 (2001), pp. 128-137
[55.]
V. Monforte, C. López, F. Santos, F. Zurbano, M. De la Torre, A. Sole, et al.
A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.
Am J Transplant, 9 (2009), pp. 1134-1141
[56.]
R.J. Stratta, C. Pietrangeli, G.M. Baillie.
Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
Pharmacotherapy, 30 (2010), pp. 144-157
[57.]
R.R. Razonable.
Cytomegalovirus infection after liver transplantation: current concepts and challenges.
World J Gastroenterol, 14 (2008), pp. 4849-4860
[58.]
R.R. Razonable, A. Rivero, A. Rodríguez, J. Wilson, J. Daniels, G. Jenkins, et al.
Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
J Infect Dis, 184 (2001), pp. 1461-1464
[59.]
M.C. Warle, A. Farhan, H.J. Metselaar, W.C. Hop, A.J. Van der Plas, M. Kap, et al.
In vitro cytokine production of TNFalpha and IL-13 correlates with acute liver transplant rejection.
Hum Immunol, 62 (2001), pp. 1258-1265
[60.]
H. Shen, D.R. Goldstein.
IL-6 and TNF-alpha synergistically inhibit allograft acceptance.
J Am Soc Nephrol, 20 (2009), pp. 1032-1040
[61.]
E. Fietze, S. Prosch, P. Reinke, J. Stein, W.D. Docke, G. Staffa, et al.
Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor.
Transplantation, 58 (1994), pp. 675-680
[62.]
C. Cervera, X. Filella, L. Linares, M. Pineda, C. Esteva, A. Antón, et al.
TH1/TH2 cytokine release pattern during in vivo cytomegalovirus disease in solid organ transplantation.
Transplant Proc, 39 (2007), pp. 2233-2235
[63.]
J.A. DesJardin, E. Cho, S. Supran, L. Gibbons, B.G. Werner, D.R. Snydman.
Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients.
Clin Infect Dis, 33 (2001), pp. 1358-1362
[64.]
P.D. Griffiths, M. Ait-Khaled, C.P. Bearcroft, D.A. Clark, A. Quaglia, S.E. Davies, et al.
Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus.
J Med Virol, 59 (1999), pp. 496-501
[65.]
A. Humar, G. Malkan, G. Moussa, P. Greig, G. Levy, T. Mazzulli.
Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients.
J Infect Dis, 181 (2000), pp. 1450-1453
[66.]
J.A. DesJardin, L. Gibbons, E. Cho, S.E. Supran, M.E. Falagas, B.G. Werner, et al.
Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection.
J Infect Dis, 178 (1998), pp. 1783-1786
[67.]
I.M. Kidd, D.A. Clark, C.A. Sabin, D. Andrew, A.F. Hassan-Walker, P. Sweny, et al.
Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection.
Transplantation, 69 (2000), pp. 2400-2404
[68.]
L. Flamand, J. Gosselin, M. D’Addario, J. Hiscott, D.V. Ablashi, R.C. Gallo, et al.
Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures.
J Virol, 65 (1991), pp. 5105-5110
[69.]
D.P. Eisen, R.M. Minchinton.
Impact of mannose-binding lectin on susceptibility to infectious diseases.
Clin Infect Dis, 37 (2003), pp. 1496-1505
[70.]
M. Kuhlman, K. Joiner, R.A. Ezekowitz.
The human mannose-binding protein functions as an opsonin.
J Exp Med, 169 (1989), pp. 1733-1745
[71.]
T. Vorup-Jensen, S.V. Petersen, A.G. Hansen, K. Poulsen, W. Schwaeble, R.B. Sim, et al.
Distinct pathways of mannan-binding lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2.
J Immunol, 165 (2000), pp. 2093-2100
[72.]
R.M. Minchinton, M.M. Dean, T.R. Clark, S. Heatley, C.G. Mullighan.
Analysis of the relationship between mannose-binding lectin (MBL) genotype. MBL levels and function in an Australian blood donor population.
Scand J Immunol, 56 (2002), pp. 630-641
[73.]
O. Manuel, M. Pascual, M. Trendelenburg, P.R. Meylan.
Association between mannosebinding lectin deficiency and cytomegalovirus infection after kidney transplantation.
Transplantation, 83 (2007), pp. 359-362
[74.]
F.J. Ghods, G. Solgi, A.A. Amirzargar, B. Nikbin, A.J. Ghods.
High frequency of clinically significant infections and cytomegalovirus disease in kidney transplant recipients with serum mannose-binding lectin deficiency.
Iran J Kidney Dis, 3 (2009), pp. 28-33
[75.]
S. Sagedal, S. Thiel, T.K. Hansen, T.E. Mollnes, H. Rollag, A. Hartmann.
Impact of the complement lectin pathway on cytomegalovirus disease early after kidney transplantation.
Nephrol Dial Transplant, 23 (2008), pp. 4054-4060
[76.]
C. Cervera, F. Lozano, N. Saval, I. Gimferrer, A. Ibáñez, B. Suárez, et al.
The influence of innate immunity gene receptors polymorphisms in renal transplant infections.
Transplantation, 83 (2007), pp. 1493-1500
[77.]
L.H. Bouwman, A. Roos, O.T. Terpstra, P. De Knijff, B. Van Hoek, H.W. Verspaget, et al.
Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation.
Gastroenterology, 129 (2005), pp. 408-414
[78.]
B.J. De Rooij, M.T. Van der Beek, B. Van Hoek, A.C. Vossen, W.R. Hove, A. Roos, et al.
Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation.
J Hepatol, 55 (2011), pp. 800-807
[79.]
B.J. De Rooij, B. Van Hoek, W.R. Ten Hove, A. Roos, L.H. Bouwman, A.F. Schaapherder, et al.
Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation.
Hepatology, 52 (2010), pp. 1100-1110
[80.]
D.L. Worthley, D.F. Johnson, D.P. Eisen, M.M. Dean, S.L. Heatley, J.P. Tung, et al.
Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation.
Clin Infect Dis, 48 (2009), pp. 410-417
[81.]
C. Cervera, D. Balderramo, B. Suárez, J. Prieto, F. Fuster, L. Linares, et al.
Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation.
Liver Transpl, 15 (2009), pp. 1217-1224
[82.]
C. Cervera, F. Lozano, L. Linares, A. Antón, D. Balderramo, B. Suárez, et al.
Influence of mannose-binding lectin gene polymorphisms on the invasiveness of cytomegalovirus disease after solid organ transplantation.
Transplant Proc, 41 (2009), pp. 2259-2261
[83.]
S. Akira, K. Takeda, T. Kaisho.
Toll-like receptors: critical proteins linking innate and acquired immunity.
Nature immunology, 2 (2001), pp. 675-680
[84.]
S. Kijpittayarit, A.J. Eid, R.A. Brown, C.V. Paya, R.R. Razonable.
Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation.
Clin Infect Dis, 44 (2007), pp. 1315-1320
[85.]
R.A. Brown, J.H. Gralewski, R.R. Razonable.
The R753Q polymorphism abrogates tolllike receptor 2 signaling in response to human cytomegalovirus.
Clin Infect Dis, 49 (2009), pp. e96-e99
[86.]
D. Ducloux, M. Deschamps, M. Yannaraki, C. Ferrand, J. Bamoulid, P. Saas, et al.
Relevance of Toll-like receptoR–4 polymorphisms in renal transplantation.
Kidney Int, 67 (2005), pp. 2454-2461
[87.]
K. Lore, M.R. Betts, J.M. Brenchley, J. Kuruppu, S. Khojasteh, S. Perfetto, et al.
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV- 1-specific T cell responses.
J Immunol, 171 (2003), pp. 4320-4328
[88.]
M.H. Yamani, R.K. Avery, S.D. Mawhorter, J.B. Young, N.B. Ratliff, R.E. Hobbs, et al.
Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection.
J Heart Lung Transplant, 20 (2001), pp. 425-430
[89.]
E. Sarmiento, J. Fernández-Yáñez, P. Muñoz, J. Palomo, J.J. Rodríguez-Molina, J. Bermejo, et al.
Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease.
Int Immunopharmacol, 5 (2005), pp. 97-101
[90.]
S. Doron, R. Ruthazer, B.G. Werner, A. Rabson, D.R. Snydman.
Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes.
Transplantation, 81 (2006), pp. 697-703
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
